|
Andrew Fraser Non-executive Director Andrew is a Partner in 3i's healthcare team. With 12 years of experience in venture capital in life sciences, he specialises in investing in medical devices and pharmaceuticals companies. Notable recent investments include HBI, Endosense, Novexel and Carmel Pharma, having previously been responsible for successful investments in Kudos Pharmaceuticals (acquired by AstraZeneca for $210m in 2006), ProStrakan ($330m IPO in London in 2005), LGC (sold for $120m in 2004) and Bradford Particle Design (acquired by Nektar Therapeutics for $200m in 2001). Andrew currently serves on the board of Healthcare Brands International and Onyvax. Prior to joining 3i, Andrew worked with Price Waterhouse in London for six years and has a honours degree in Business from Edinburgh University. | 